These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9916557)

  • 21. Anticoagulation with warfarin. A review of monitoring issues.
    Vogel E
    Adv Nurse Pract; 2001 Jan; 9(1):75-8, 81, 94. PubMed ID: 12416044
    [No Abstract]   [Full Text] [Related]  

  • 22. Self-monitoring and self-management of anticoagulation therapy.
    Cayley WE
    Am Fam Physician; 2011 Aug; 84(3):266-8. PubMed ID: 21842772
    [No Abstract]   [Full Text] [Related]  

  • 23. Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administration.
    Rosborough TK; Jacobsen JM; Shepherd MF
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):433-5. PubMed ID: 19543077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the performance verification of the CoaguChek XS system.
    Plesch W; Wolf T; Breitenbeck N; Dikkeschei LD; Cervero A; Perez PL; van den Besselaar AM
    Thromb Res; 2008; 123(2):381-9. PubMed ID: 18585761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.
    Nochowitz B; Shapiro NL; Nutescu EA; Cavallari LH
    Ann Pharmacother; 2009 Jul; 43(7):1165-72. PubMed ID: 19549747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.
    Crowther MA
    Semin Vasc Med; 2003 Aug; 3(3):255-60. PubMed ID: 15199458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing an oral anticoagulant monitoring service in a multiethnic developing country.
    Casimire T; Carter R; Peters S; Tweedle J; Charles KS
    Int J Lab Hematol; 2008 Dec; 30(6):531-5. PubMed ID: 18983306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant.
    Sanfelippo MJ; Sennet J; McMahon EJ
    WMJ; 2000 Jun; 99(3):62-4, 43. PubMed ID: 10927985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation.
    Tripodi A; Bressi C; Carpenedo M; Chantarangkul V; Clerici M; Mannucci PM
    Thromb Res; 2004; 113(1):35-40. PubMed ID: 15081563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility, cost-effectiveness and patients' acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic.
    Kong MC; Lim TG; Ng HJ; Chan YH; Lee LH
    Ann Hematol; 2008 Nov; 87(11):905-10. PubMed ID: 18604535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Self-monitoring of oral anticoagulation therapy in children.
    Paioni P; Kroiss S; Kägi E; Bergsträsser E; Fasnacht M; Bauersfeld U; Schmugge M; Albisetti M
    Acta Haematol; 2009; 122(1):58-63. PubMed ID: 19816011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management.
    Ansell JE
    Semin Vasc Med; 2003 Aug; 3(3):261-70. PubMed ID: 15199459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study.
    Menzin J; Boulanger L; Hauch O; Friedman M; Marple CB; Wygant G; Hurley JS; Pezzella S; Kaatz S
    Ann Pharmacother; 2005 Mar; 39(3):446-51. PubMed ID: 15701783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The North American experience with patient self-testing of the INR.
    Jacobson AK
    Semin Vasc Med; 2003 Aug; 3(3):295-302. PubMed ID: 15199463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarin.
    Lee W; Chung HJ; Kim S; Jang S; Park CJ; Chi HS; Chun S; Min WK
    Clin Biochem; 2010 Sep; 43(13-14):1177-9. PubMed ID: 20621074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance improvement in managed long-term care: improving warfarin medication management.
    Desmond D; Kogan P; Underwood S; Brobbey E; Luib P
    Home Healthc Nurse; 2009 Mar; 27(3):150-9. PubMed ID: 19279480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Audit of community-based anticoagulant monitoring in patients with thromboembolic disease: is frequent testing necessary?
    Young L; Ockelford P; Harper P
    Intern Med J; 2004 Nov; 34(11):639-41. PubMed ID: 15546458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CoaguChek point-of-care testing prothrombin time monitors.
    Braun SL
    Am J Clin Pathol; 2007 Oct; 128(4):671-2; author reply 672. PubMed ID: 17924500
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term standard-dose warfarin to prevent thrombosis.
    Depenbrock PJ
    Am Fam Physician; 2005 Jul; 72(1):36, 41. PubMed ID: 16035681
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.